Chiamaka Iheme, MD
Family Medicine · Palm Coast, FLNPI 1326479460
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novo Nordisk at 48.3% of the total. Reporting peaked in 2022 at $534 and has fallen 93.7% since, to $34 in 2023.
Across 59 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$527
- Merck$90
- AstraZeneca$70
- Lilly USA, LLC$62
- AbbVie$60
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
- plus $223 from 9 others
Across 30 payments — averaging $347,146 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$6.3M
- Beigene USA, Inc.$1.9M
- E.r. Squibb & Sons, L.L.C.$1.7M
- Genentech, Inc.$517K
What the payments were for
- Food & beverage$1,091100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $527 |
| Merck | 6 | $90 |
| AstraZeneca | 4 | $70 |
| Lilly USA, LLC | 4 | $62 |
| AbbVie | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Boehringer Ingelheim | 3 | $39 |
| Almatica Pharma LLC | 2 | $38 |
| GSK | 2 | $37 |
| Amarin Pharma, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Bayer | 1 | $19 |
| Global Blood Therapeutics, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Amgen | 1 | $15 |
How this compares
$1,091 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $24,281 |
| EliquisApixaban | 12 | $10,346 |
| Atorvastatin Calcium | 186 | $2,357 |
| SynthroidLevothyroxine Sodium | 29 | $1,940 |
| Losartan Potassium | 134 | $1,729 |
| Levothyroxine Sodium | 133 | $1,697 |
| Rosuvastatin Calcium | 87 | $1,318 |
| Amlodipine Besylate | 124 | $1,106 |
| Gabapentin | 35 | $827 |
| Omeprazole | 54 | $752 |
| Glipizide | 21 | $729 |
| Pantoprazole Sodium | 44 | $679 |
| Tamsulosin Hcl | 53 | $665 |
| Famotidine | 29 | $663 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $527 | $24,28124 claims |
| AbbVieSynthroid | $60 | $1,94029 claims |
| Almatica Pharma LLCSertraline Hcl | $38 | $32532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Palm Coast
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.